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doi:10.1016/j.jtcvs.2007.09.0411054 The Journal of Thoracic and CarObjectives: Peak oxygen uptake (VO2) and ventilatory efficiency have prognostic
implications in the population with congestive heart failure. This study evaluated
quality-of-life functional capacity after the 2 treatment strategies of surgical ventric-
ular restoration and transplantation for severe left ventricular dysfunction of ischemic
cause.
Methods: The 75-patient study population (between 2004 and 2006) with severe heart
failure included 35 patients undergoing surgical ventricular restoration (mean age,
62.6 6 8.7 years), sometimes together with coronary artery bypass grafting or mitral
surgery, and 40 cardiac transplant recipients (mean age, 55.6 6 7.7 years). Preoper-
ative and 6-month postoperative function (peak VO2, the anaerobic threshold, and the
slope of minute ventilation/carbon dioxide uptake), cardiac catheterization parameters
(left and right), and hospital and early outcomes were evaluated.
Results: The 2 groups had comparable baseline functional impairment and experi-
enced similar hospital stay and early outcomes. They also showed similar improve-
ments in left ventricular volume indexes and hemodynamic parameters and
sustained significant improvements of median VO2, anaerobic threshold, and minute
ventilation/carbon dioxide uptake values.
Conclusions: Both surgical strategies resulted in a significant and comparable
improvement of functional capacity at the 6-month evaluation. These early studies
must be repeated to determine the long-term benefits of surgical ventricular restoration
because maximal VO2 and ventilatory efficiency lose their prognostic survival role
after transplantation.
I
schemic left ventricular dysfunction continues to represent a major health care
problem because it affects approximately two thirds of the patients referred for
congestive heart failure. Limitations in organ procurement severely restrict the
use of heart transplantation, make listing criteria increasingly selective, and strongly
support the development of alternative surgical approaches. Dor’s pioneering experi-
ence1 has established the role of surgical ventricular restoration (SVR) to treat ische-
mic cardiomyopathy after the nidus of a large myocardial scar causes progressive
cardiac dilation of remote muscle from adverse remodeling. SVR improves ventricu-
lar performance and functional class, with a gratifying 5-year survival and low rate of
rehospitalization for heart failure,2,3 but the merits, indications, and long-term efficacy
of this strategy remain under intense investigation.
Our prior study compared SVR and transplantation treatment of severe ischemic
dilated cardiomyopathy4 and showed that ventricular reconstructive surgery provided
a significant improvement in cardiac function, allowing for a better quality of life and
a lower risk of rehospitalization than transplantation but higher hospital mortality.
Absent from that analysis were measurements after cardiopulmonary exercise testingdiovascular Surgery c May 2008
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CPET 5 cardiopulmonary exercise testing
EF 5 ejection fraction
NYHA 5 New York Heart Association
SVR 5 surgical ventricular restoration
VE 5 minute ventilation
VO2 5 oxygen uptake
(CPET), which is a noninvasive way of evaluating patients
with heart failure and is used consistently in the assessment
for cardiac transplantation. Values gleaned from analyzing
these test results have been a guide to treatment strategy
choices used to determine long-term survival5,6 but have
not yet been compared with values achieved after SVR for
dilated ischemic cardiomyopathy. The goal of evaluating
patients with end-stage ischemic cardiomyopathy is to deter-
mine how oxygen uptake (VO2) during exercise is changed
after treatment with either ventricular restoration or heart
transplantation at the 6-month postoperative interval.
Materials and Methods
Study Design
This is a single-center prospective study analyzing the experience
over 18months with surgical treatment of ischemic cardiomyopathy.
From January 2004 through June 2006, 200 patients were operated
on for ischemic cardiomyopathy at the Department of Cardio-
Thoracic Sciences, Second University of Naples, ‘‘V. Monaldi’’
Hospital. Inclusion criteria for the present study were end-stage
ischemic cardiomyopathy, defined according to Burch and col-
leagues7; end-systolic volume index of 50 mL/m2 or greater; and
an ejection fraction (EF) of 35% or less, excluding cases of isolated
lateral or posterior wall aneurysm. Thus the analysis included 75 pa-
tients (53 male and 22 female patients) between 41 and 75 years of
age (mean age, 60.66 5.2 years) divided into 2 groups. Group A in-
cluded 35 patients (mean age, 62.66 8.7 years; 10 female patients)
who underwent SVRwith endoventricular circular patch plasty asso-
ciated with coronary artery bypass grafting, mitral surgery, or both.
Group B included 40 recipients who underwent orthotopic cardiac
transplantation (mean age, 55.6 6 7.7 years; 12 female patients).
Patient–Procedure Matching Criteria
Choice of surgical treatment was based on morphologic and func-
tional cardiac parameters, but the SVR exclusion criteria, according
to Dor,8 included (1) severely decreased right ventricular function,
(2) lack of ischemic areas suitable for revascularization, and (3)
lack of contraction improvement of basal segments during echo-
dobutamine. Conversely, age greater than 65 years was a relative
contraindication to heart transplantation because of the shortage of
available donor organs and the high likelihood of waiting-time
decompensation.
Surgical Procedures
All the restoration procedures were performed bymeans of a median
sternotomy using mild hypothermic (28C) cardiopulmonaryThe Journal of Thorabypass, aortic crossclamping, and myocardial protection with inter-
mittent St Thomas I perfusion. The strategy included (1) endoven-
tricular patch plasty according to the principles of Dor’s technique
with our modifications, (2) repair of the regurgitant mitral valve
(28.5%) with either Alfieri or Bolling techniques, and (3) coronary
bypass grafting to provide complete revascularization (2.1 6 0.9
grafts in 32 patients). Map-guided cryoablation was performed in
8.5% of patients with preoperative ventricular arrhythmias. Prophy-
lactic intra-aortic balloon counterpulsation was instituted just before
induction of anesthesia in 22.8% of patients with pronounced con-
gestive heart failure to achieve intraoperative hemodynamic stability
and prevent low postoperative cardiac output. Outpatient follow-up
management included maintenance of an optimal heart failure regi-
men includingb-blockers and angiotensin-converting enzyme inhib-
itors, which were administered by our clinic physicians.
During transplantation, the donor heart was procured by using
standard techniques and was protected with 2 L of cold (4C to
8C) Celsior solution (Genzyme Corporation, Cambridge, MA)
and topical saline slush. Excised grafts were then immersed in 1 L
of cold Celsior solution and stored on ice in a closed cardiac storage
container for transportation. All recipients underwent standard or-
thotopic transplantation by using the atrial anastomotic technique.
Principles of posttransplantation care and immunosuppressive regi-
men have been described elsewhere.9
Cardiac Rehabilitation Program
All patients in both groups enrolled in a comprehensive postopera-
tive exercise rehabilitation program based on protocols designed
by the European Heart Failure Training Group and the American
Heart Association Committee on Exercise, Rehabilitation, and
Prevention.10,11
CPET and Heart Catheterization
Patients underwent exercise testing and heart catheterization during
the preoperative evaluation and 6 months after the surgical proce-
dure. Endomyocardial biopsy demonstrating the absence of acute
rejection was required in patients undergoing heart transplantation
before undergoing CPET postoperatively. All patients performed
upright bicycle exercise to maximum tolerance with the use of a pro-
gressively increasing work rate at 10 to 20 W/min after a period of
resting and unloaded pedaling, as recommended by Buchfuhrer and
associates.12 Patients were encouraged to exercise until symptoms
were intolerable. Investigator-determined exercise end points were
severe ventricular tachycardia of 5 beats or greater, high degree of
atrioventricular block, ST-segment depression of 3 mm or greater,
systolic blood pressure of 250 mm Hg or greater, or progressive
decrease in blood pressure. Breath-by-breath gas exchange mea-
surements were performed with a Cosmed Quark (PFT Ergo,
Rome, Italy) metabolic cart. VO2, carbon dioxide output, tidal vol-
ume, and breathing rate were measured. Blood gases (PaO2 and
PaCO2) and pH were measured at rest and shortly before the end
of exercise with the use of arterialized capillary blood samples.
From the above data, minute ventilation (VE), and the ventilatory
equivalents for CO2 were calculated. Peak VO2 was determined as
the highest VO2 achieved during exercise. The anaerobic threshold
(VO2 anaerobic threshold) was measured by using the V-slope
method. Typical changes in ventilatory equivalents and end-tidal
gas concentrations were examined to search for agreement in cases
that were questionable with regard to the precise VO2 anaerobiccic and Cardiovascular Surgery c Volume 135, Number 5 1055
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means of linear regression, excluding the nonlinear part of the
data after the onset of ventilatory compensation for metabolic acido-
sis. The 6-minute walking distance, a test widely used for its ease of
administration and reproducibility, was not performed in the present
study. However, the CPET is noninvasive, more discriminating, and
above all more useful in comparing different treatment groups in
that it is more sensitive in detecting even small differences in exer-
cise capacity.13
The most recent right heart catheterization was used to measure
preoperative cardiac hemodynamic data: mean pulmonary artery
pressure, systolic pulmonary artery pressure, diastolic pulmonary
artery pressure, pulmonary capillary wedge pressure, cardiac index,
and pulmonary vascular resistance index. The same hemodynamic
parameters were obtained from the postoperative Swan–Ganz cath-
eter measurements. Coronary catheterization and left ventriculogra-
phy were contemporarily performed. Each angiogram was reviewed
in detail, independent of the clinical review. The angiograms were
reviewed by 2 observers familiar with the spectrum of allograft cor-
onary artery disease to arrive at a consensus regarding the subjective
grading of these films; the modified classification proposed by Gao
and coworkers14 was used. Abnormalities were classified to distin-
guish involvement of proximal epicardial large vessels and distal
small vessels (tertiary branches or greater), as well as the character
and extent of luminal encroachment (mild diffuse luminal irregular-
ity, focal stenosis, or diffuse vascular obliteration), as defined by
Gao and coworkers.14 The finding of focal angiographic stenosis
of 70% or greater or evidence of diffuse large- or small-vessel oblit-
eration defined ‘‘severe’’ disease. The images of left cine ventriculo-
grams were digitized to obtain the left ventricular volume by means
of biplane analysis. The left ventricular end-systolic volume index,
left ventricular end-diastolic volume index, and EF were calculated.
Follow-up and Statistical Analysis
All preoperative, hospital, and follow-up data (total follow-up, 1182
months per patient; mean follow-up of group A, 16.96 6.9 months;
mean follow-up of group B, 17.4 6 8.5 months) were recorded in
a dedicated electronic database. Hospital mortality was defined as
death before the 30th postoperative day. SPSS software (version
10.1; SPSS, Inc, Chicago, Ill) was used for statistical analysis.
Data were expressed as means6 standard deviations for continuous
variables or counts and percentages for categorical variables. Anal-
ysis of variance and c2 Pearson or Fisher exact tests were used for
statistical evaluation of the differences between groups. Two-tailed
paired t tests were used for intragroup comparisons of hemodynamic
and functional data (before treatment vs after treatment). Nonpara-
metric tests were used in case of skewed distribution.
The authors had full access to the data and take responsibility for




Table 1 presents the preoperative clinical and demographic
features of the patient population. Those offered orthotopic
transplantation were younger because of the age restriction
of transplant candidacy and had more prior cardiac opera-
tions. Both groups had a similar sex distribution, incidence1056 The Journal of Thoracic and Cardiovascular Surgery c Mof diabetes, New York Heart Association (NYHA) class,
presence and degree of mitral regurgitation, and comparable
mean time interval between diagnosis and surgical interven-
tion.
Postoperative Data and Hospital and Postdischarge
Outcomes
Hospital mortality was not different between the 2 treatments
(11.4% vs 7.5%). After SVR, mortality was from low cardiac
output in 3 patients and multiorgan failure in 1 patient. The 3
posttransplantation deaths were due to acute graft failure in 1
patient, pneumonia in 1 patient, and multiorgan failure in 1
patient. Global systolic function improved postoperatively in
survivors in both groups. The EF increased from 28.1% 6
7.3% preoperatively to 34.5% 6 9.3% postoperatively in
group A (P , .001) and from 27.3% 6 6% to 49.8% 6
7% in group B (P , .001). During follow-up, one sudden
death occurred after SVR, and 1 death from acute rejection
occurred after transplantation. Two patients in group A and
1 in group B experienced heart failure recurrence. Of these,
the patients undergoing SVR and experiencing heart failure
recurrence had very severe preoperative ventricular enlarge-
ment associated with mitral regurgitation, poor coronary
targets for revascularization, or both.
CPET and Cardiac Catheterization Analysis
Similar symptom improvement occurred in both groups
because mean postoperative NYHA class decreased from
3.36 0.2 and 3.26 0.18 to 1.76 1.1 and 1.36 0.3, respec-
tively. Left heart catheterization disclosed no evidence of
allograft coronary disease in heart transplant recipients. All
bypass grafts except 1 were patent in group A. Table 2 sum-
marizes cardiac catheterization data, CPET results, and
Weber–Janicki class assessment and medical therapy. In
comparison with preoperative status, surgical intervention
conferred a significant and homogeneous functional benefit







Age (y) 62.6 6 8.7 55.6 6 7.7 .001
Female sex 10 (28.6%) 12 (30%) NS
Diabetes 13 (37.1%) 15 (37.5%) NS
Prior CABG 10 (28.6%) 22 (55%) .013
Preoperative
NYHA
3.2 6 0.2; 29
(82.8%); 6
(17.2%)




Preoperative EF (%) 27.1 6 4.5 25.3 6 7.5 NS
Presence of MR 37.1% 47.5% NS
MR $grade 2 28.5% 42.5% NS
Time to operation (mo) 42.9 6 56 40.2 6 51.7 NS
NS, Not significant; CABG, coronary artery bypass grafting; NYHA, New
York Heart Association; EF, ejection fraction; MR, mitral regurgitation.ay 2008
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Group A Group B
Preoperative Postoperative Preoperative Postoperative
LVEDVI (mL/m2) 113 6 63 79 6 23* 115 6 75 68 6 12*
LVESVI (mL/m2) 77.4 6 41 53 6 24* 78.6 6 31.2 27 6 8*
VO2 peak (mL $ kg
21 $ min21) 12 6 1.3 16 6 1.5* 9.5 6 3 15.2 6 0.8*
AT (mL $ kg21 $ min21) 9.1 6 0.9 11 6 1* 8.4 6 0.7 12 6 1*
VE/VCO2 slope 34.8 6 8.5 29.2 6 9.9* 38.4 6 6 31.4 6 3.8*
CI (L $ min21 $ m22) 1.82 6 0.88 2.82 6 0.47* 1.7 6 0.45 2.75 6 0.52*
PVRI (WU/m2) 4.85 6 1.8y 2.98 6 0.68* 5.8 6 1.4 2.78 6 1.6*
PAP mean (mm Hg) 42 6 12.11 26.8 6 4* 39 6 11 22 6 7*
PCP (mm Hg) 16 6 4.9y 14 6 6.2* 25 6 9 12 6 4*
Medication
b-Blockers 29 (82.8%)y 25 (80.6%) 34 (85%) 4 (10.8%)*
ACE inhibitors 33 (94.3%) 28 (90.3%) 39 (97.5%) 25 (67.6%)
Diuretic 20 (57.2%) 15 (48.3%) 32 (80%) 12 (32.4%)
Spironolactone 20 (57.2%) 16 (51.6%) 33 (82.5%) 2 (5.4%)
Digoxin 23 (65.7%) 12 (38.7%) 21 (52.5%) —
Anticoagulants/aspirin 26 (74.4%) 31 (100%) 40 (100%) 37 (100%)
Weber–Janicki class
A — —* — —*
B 2 (5.7%) 14 (45.2%) 1 (2.5%) 15 (40.5%)
C 26 (74.3%) 16 (51.6%) 31 (77.5%) 20 (54%)
D 7 (20%) 1 (3.2%) 8 (20%) 2 (5.5%)
E — — — —
LVEDVI, Left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; VO2, oxygen uptake; AT, anaerobic threshold; VE /VCO2,
minute ventilation/carbon dioxide uptake; CI, cardiac index; PVRI, pulmonary vascular resistance index; PAP, pulmonary artery pressure; PCP, Pulmonary cap-
illary pressure; ACE, angiotensin-converting enzyme. *P , .05, preoperative versus postoperative. yP , .05, preoperative group A versus group B.A
CDin both groups, as shown in Table 2. However, transplant
recipients required significantly less cardiovascular therapy
but needed an immunosuppressive regimen.
Discussion
This prospective review, evaluating functional recovery of
patients affected by ischemic cardiomyopathy treated either
with heart transplantation or left ventricular restoration,
showed similar improvement with both methods, thereby
implying that absence of donor heart availability does not
diminish the performance benefit gained from using the
patients’ own tissues to surgically reconstitute cardiac size
and shape. The most important findings show that both strat-
egies (1) result in similar hospital and early outcomes and (2)
confer a comparable functional parameter improvement after
measurement by means of cardiopulmonary exercise and
clinical assessment. In this perspective it should be noted
that although patients undergoing transplantation were con-
sidered unsuitable for any other surgical therapy, many of
the patients receiving SVR could have been offered heart
transplantation based on their preoperative CPET parameters
(mean maximal VO2, 12 6 1.3 mL $ kg
21 $ min21). How-
ever, the degree of CPET performance observed after SVR
might imply a significant prognostic benefit based on prior
reports in patients undergoing transplantation.5,6The Journal of ThoraPrognostic Role of CPET in Heart Failure
The value of CPET after heart failure is the capacity to place
a numeric value on the ability to exercise and thereby convey
a more realistic measure of efficiency of cardiac output to
supply oxygen for body needs than is available from the
more subjective NYHA classification. Of equal importance
is that CPET is a pivotal modality in the initial evaluation
of patients with advanced heart failure15 during evaluation
for transplantation, yet is infrequently used in heart failure
clinics for patients not considered for transplantation. For ex-
ample, Mancini and associates16 found that peak VO2 was the
single best predictor of survival in patients considered for car-
diac transplantation. Recent studies of ventilatory expired gas
parameter show that a high VE/VCO2 ratio at peak exercise or
a high slope at submaximal exercise provides a powerful
independent index of poor prognosis.17 Furthermore, the
mortality rate of patients with a maximal VO2 of 14.5 mL $
kg21 $ min21 or less was twice that of patients whose max-
imal VO2 exceeded this value in the Veterans Administration
Heart Failure Trial, and this functional test exerted a stronger
predicting role than the type of drug treatment.18
Effects of SVR and Heart Transplantation on
Hemodynamic and CPET Performance
Previous studies have demonstrated that SVR significantly
improves EF, left ventricular size, left ventricular shape,cic and Cardiovascular Surgery c Volume 135, Number 5 1057
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patients with congestive heart failure. Studies have also
shown that SVR improves mechanical dyssynchrony, levels
of neurohormones associated with congestive heart failure,
cardiac function in high-risk surgical candidates, and myo-
cardial performance in nonischemic areas remote from
scars.1-3,19-21 Each of these factors improves tissue oxygen
delivery and is the infrastructure of the reported CPET find-
ings, which, to our knowledge, are the first evidence of signif-
icant improvements both in CPET and hemodynamic
performance after ventricular restoration. The degree of post-
operative dimensional and hemodynamic improvement pre-
sented in this series is consistent with prior data19,21 and is
due to the following surgically induced changes: (1) com-
plete revascularization that includes reperfusion of the upper
part of the septum; (2) patient-tailored reduction of ventricu-
lar volume by means of exclusion of septal, anterior, and in-
ferior components, together with lowering ventricular wall
stress and improving remote zone mechanical efficiency;
(3) restoration of the physiologically elliptical left ventricular
shape to optimize mechanical efficiency while both avoiding
incorrect positioning of the papillary muscles and worsening
of diastolic dysfunction; and (4) correction of mitral regurgi-
tation, as described by Menicanti and colleagues.22,23
Despite improvement in survival and symptoms attribut-
able to transplantation, exercise capacity, as assessed by
means of CPET, remains markedly impaired when compared
with that of healthy individuals and might not be different
from that of medically stabilized patients with heart fail-
ure.5,24 Hence some cardiac transplant recipients, such
as those included in the present work, have disappointing
exercise performance that impairs quality of life, despite ap-
parently normal resting cardiac function. Responsible mech-
anisms that limit normal return of peak exercise capacity in
this transplant cohort include parasympathetic and sympa-
thetic cardiac denervation that increases resting heart rate,
attenuates heart rate response at peak exercise, and delays
normalization of heart rate after exercise. Furthermore, dia-
stolic dysfunction and limited cardiac contractile reserve
allow contractile impairment to supplement these chrono-
tropic changes, and these mechanical alterations occur simul-
taneously with altered peripheral circulatory mechanisms in
transplant recipients24 and might be worsened in patients
with higher NYHA status in ischemic transplant recipi-
ents.6,25 These data were determined only 6 months after
transplantation and without evidence of secondary coronary
disease but directly mirror the Registry of the International
Society for Heart and Lung Transplantation,26 which shows
that peak oxygen consumption might lose prognostic signif-
icance after transplantation.
Clinical Implications
The significant functional recovery observed in this study
might indicate an improved long-term prognosis after SVR1058 The Journal of Thoracic and Cardiovascular Surgery c Msurgery because improved oxygen consumption is associated
with lower mortality, as shown by Lund and coworkers,27
who studied the prognostic value of peak VO2 in 227 adults
with heart failure who were reevaluated more than 60 days
after initial evaluation. Patients whose values improved
from a high- or medium-risk Heart Failure Survival Score
or peak VO2 values (,10 mL $ kg
21 $ min21 and 10–14
mL $ kg21 $ min21, respectively) to lower-risk values
(.14 mL $ kg21 $ min21) had 1-year event-free survival
rates of 89% and 83% after b-blocker therapy alone and
were thereby removed from the transplant waiting list.27,28
Furthermore, transplantation could be safely deferred in
patients whose peak VO2 value was 14 mL $ kg
21 $ min21
or greater, where their survival exceeded that of patients
undergoing heart transplantation.15 Notably, the mean post-
transplantation peak VO2 value of 16 6 1.5 mL $ kg
21 $
min21 was less than the normal value threshold of greater
than 18 mL $ kg21 $ min21, which seemed to unfavorably
compare with the reports of Leung and associates5; however,
in that study only one third of patients had ischemic causes,
and they were remarkably younger (mean age, 48 years)
and had higher preoperative functional capacity (preopera-
tive peak VO2, 16 mL $ kg
21 $ min21) than in the present
experience.
In our study mean postoperative peak VO2 in patients
undergoing SVRwas 166 1.5 mL $ kg21 $min21, thus con-
ferring a lower-risk prognosis to an initially high-risk cohort.
Similar better prognosis considerations exist after VE/VCO2
slope analysis because the mean postoperative values
in this report are lower than the greater than 34 cutoff known
to imply a poor prognosis.29 The selection of a 6-month
interval for the first measurement might provide an early as-
sessment because neuroendocrine changes recover over
1 year,19 so that subsequent testing is needed to determine
whether there is further improvement. SVR also avoids the
aforementioned chronotropic and mechanical changes after
transplantation, so that these observations suggest that the
mortality of patients with ischemic cardiomyopathy can be
significantly reduced by means of restoration surgery; remote
muscle function might progressively improve, and the risk of
secondary coronary disease after transplantation is avoided.
Further testing is also essential to determine whether ventric-
ular redilation is prevented because increased ventricular
volume will counteract these positive results.
This study compared CPET results of SVR with those of
heart transplantation. Another therapeutic option used for
specific subsets of patients with dilated cardiomyopathy is
resynchronization, and comparative studies could be per-
formed, using VO2 as an end point. To date, in a randomized
study30 a slight improvement in peak VO2 value has been
reported, and a recent study has claimed an increase of peak
VO2 value from 13 to 14.8 mL $ kg
21 $min21 at 12months,31
which is lower than our 6-month value, but no comparison
with other treatment modalities has been carried out.ay 2008
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This study analyzed the effect of SVR surgery on CPET
performance in a small number of patients. Importantly, the
improvement of left ventricular function in the patients stud-
ied is in close agreement with previous reports from our insti-
tution4 and from larger series,1-3,20-23 indicating that the
patients enrolled in this study are indeed representative.
SVR represents a surgical strategy aimed to correct all the an-
atomic and functional determinants of heart failure in ische-
mic cardiomyopathy. In doing so, our efforts are directed
toward the vessel, valve, and ventricle, so that evaluation of
the relative merits of each single operative step on functional
and hemodynamic results is hampered, especially because
continued medical therapy and the comprehensive rehabilita-
tion programmight have contributed to the improvement. The
limited study sample prevented us from stratifying patients
according to preoperative features (ie, mitral regurgitation,
larger ventricles, and viability of remote areas), and the short
6-month follow-up analysis prevents any speculation on left
ventricular redilatation late after surgical intervention, even
though the stability of SVR results is supported by the studies
ofDor and colleagues.32 A longer follow-up (at least 1 year) is
also needed to investigate the effects of late neuroendocrine
rearrangements after ventricular volume change.
Conclusions
SVR is a comprehensive surgical approach tailored to
address all pathophysiologic ventricular geometric factors
contributing to heart failure development in ischemic pa-
tients, and application of this procedure provided a cohort
of hospital survivors displaying the same significant CPET
performance and hemodynamic improvement observed in
a cohort of patients undergoing transplantation. These results
support the hypothesis that direct improvement of cardiovas-
cular function and optimization of ventricular geometry
might improve functional capacity by acting on the intracar-
diac determinants of cardiac dysfunction, together with
simultaneous correction of vessel and valve factors. Further
studies are required to determine the durability of functional
improvement because this favorable response after SVR
might imply a long-term survival benefit that is associated
with a better quality of life than currently available with either
conventional treatments or after the use of cardiac transplan-
tation, which has a limited number of available donor organs.
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